Skip to content

Released May 10, 2017, after the close

10-Q filed May 10, 2017, 40 days after period end · 0001144204-17-026034

Q1 2017 · 10-Q
Revenue$2.89M+325.5% vs Q1 2016+38.8% vs Q4 2016
Net Income-$59.15MN/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$0.48N/M vs Q1 2016no prior Q4 2016 on file
Gross Profit$801,000+413.5%
Operating Income-$6,365,000N/M
Operating Cash Flow-$8,426,000N/M
Free Cash Flowderived-$8,646,000N/M
Margins · derived
Gross margin27.7%+4.8 pt vs Q1 2016
Operating margin-220.3%+937.9 pt vs Q1 2016
Net margin-2047.4%−781.1 pt vs Q1 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2017Q1 2016Q1 2015Q1 2014
Revenue$2.89M$679.00K$1.69M$6.70M
Net Income-$59.15M-$8.60M-$5.97M-$7.35M
EPS Diluted-$0.48-$0.09-$0.06$0.08

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR